Bcl2-negative follicular lymphomas frequently have Bcl6 translocation and/or Bcl6 or p53 expression

Pathology International

Volumn 57, Issue 3, 2007, Pages 148-152

  Guo, Ying ^a   Karube, Kennosuke ^b   Kawano, Riko ^a   Suzumiya, Junji ^a   Takeshita, Morishige ^a   Kikuchi, Masahiro ^a   Huang, Gao Sheng ^d   Li, Qing ^d   Ohshima, Koichi ^c  

^a FUKUOKA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bcl2; Bcl6; Follicular lymphoma

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN BCL X; PROTEIN P53;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CELL PROLIFERATION; DNA-BINDING PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPH NODES; LYMPHOMA, FOLLICULAR; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846917666     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2006.02072.x     Document Type: Article

References (26)

1. Nathwani B, Harris N, Weisenburger D et al. Follicular lymphoma. In: Jaffe ES, Harris NL, Stein H et al., eds. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001; 162-7.
2. Guo Y, Karube K, Kawano R et al. Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances. Leukemia 2005; 19: 1058-63.
3. Horsman DE, Okamoto I, Ludkovski O et al. Follicular lymphoma lacking the t(14;18)(q32;q21): Identification of two disease subtypes. Br J Haematol 2003; 120: 424-33.
4. Bosga-Bouwer AG, van den Berg A, Haralambieva E et al. Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? Hum Pathol 2006; 37: 528-33.
5. Bosga-Bouwer AG, van Imhoff GW, Boonstra R et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood 2003; 101: 1149-54.
6. Zha H, Raffeld M, Charboneau L et al. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest 2004; 84: 235-44.
7. Nguyen PL, Zukerberg LR, Benedict WF, Harris NL. Immunohistochemical detection of p53, bcl-2, and retinoblastoma proteins in follicular lymphoma. Am J Clin Pathol 1996; 105: 538-43.
8. Cooper K, Haffajee Z. bcl-2 and p53 protein expression in follicular lymphoma. J Pathol 1997; 182: 307-10.
9. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 1997; 276: 589-92.
10. Ye BH, Cattoretti G, Shen Q et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet 1997; 16: 161-70.
11. Ye BH, Lista F, Lo Coco F et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 1993; 262: 747-50.
12. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004; 432: 635-9.
13. Zhang X, Karnan S, Tagawa H et al. Comparison of genetic aberrations in CD10+ diffused large B-cell lymphoma and follicular lymphoma by comparative genomic hybridization and tissue-fluorescence in situ hybridization. Cancer Sci 2004; 95: 809-14.
14. Jardin F, Gaulard P, Buchonnet G et al. Follicular lymphoma without t(14;18) and with BCL-6 rearrangement: A lymphoma subtype with distinct pathological, molecular and clinical characteristics. Leukemia 2002; 16: 2309-17.
15. Aster JC, Longtine JA. Detection of BCL2 rearrangements in follicular lymphoma. Am J Pathol 2002; 160: 759-63.
16. Danial NN, Korsmeyer SJ. Cell death: Critical control points. Cell 2004; 116: 205-19.
17. Boise LH, Gonzalez-Garcia M, Postema CE et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
18. Xerri L, Hassoun J, Devilard E, Birnbaum D, Birg F. BCL-X and the apoptotic machinery of lymphoma cells. Leuk Lymphoma 1998; 28: 451-8.
19. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82: 2289-95.
20. Sander CA, Yano T, Clark HM et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82: 1994-2004.
21. Ott G, Katzenberger T, Lohr A et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002; 99: 3806-12.
22. Miyashita T, Krajewski S, Krajewska M et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-805.
23. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Downregulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994; 54: 2095-7.
24. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994; 145: 1191-8.
25. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995; 55: 237-41.
26. Pezzella F, Morrison H, Jones M et al. Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma. Histopathology 1993; 22: 39-44.